BDI Pharma's blog

We see it in the headlines every day—a new specialty drug is either coming out of clinical trial or has been approved.

It’s no surprise that the growth in U.S. drug spending is rapidly shifting from traditional to specialty drugs, especially as the development of new drugs becomes more targeted and expanded indications are being granted for previously approved drugs.